Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU‐MP‐1, protects the heart against adverse effects during pressure overload

BACKGROUND AND PURPOSE: The Hippo pathway has emerged as a potential therapeutic target to control pathological cardiac remodelling. The core components of the Hippo pathway, mammalian Ste‐20 like kinase 1 (Mst1) and mammalian Ste‐20 like kinase 2 (Mst2), modulate cardiac hypertrophy, apoptosis, and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Pharmacol
Egile Nagusiak: Triastuti, Efta, Nugroho, Ardiansah Bayu, Zi, Min, Prehar, Sukhpal, Kohar, Yulia Suciati, Bui, Thuy Anh, Stafford, Nicholas, Cartwright, Elizabeth J., Abraham, Sabu, Oceandy, Delvac
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Research Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811740/
https://ncbi.nlm.nih.gov/pubmed/31328787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14795
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak